🇺🇸 FDA
Pipeline program

SYS6055

IIT2026024

Phase 1 small_molecule active

Quick answer

SYS6055 for Relapsed/Refractory B-Cell Malignancies is a Phase 1 program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Relapsed/Refractory B-Cell Malignancies
Phase
Phase 1
Modality
small_molecule
Status
active

Clinical trials